

# Clinical trials of dipyridamol + aspirin

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 post myocardial infarction

Trial	Treatments	Patients	Trials design and methods
<b>dipyridamol + aspirin vs placebo</b>			
<b>PARIS , 1980</b> n=810/406 follow-up: 41 months (mean)	Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Placebo	patients who had recovered from myocardial infarction	Parallel groups Double blind USA and UK
<b>PARIS-II , 1986</b> n=1563/1565 follow-up: 23.4 months	Aspirin (330 mg) + dipyridamole (75 mg) 3x/d versus Placebo	patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously	Parallel groups Double blind USA and UK
<b>dipyridamol + aspirin vs aspirin</b>			
<b>PARIS , 1980</b> n=810/810 follow-up: 41 months	Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Aspirin (324 mg) 3x/d	patients who had recovered from myocardial infarction	Parallel groups Double blind USA and GB

More details and results :

- antiplatelets drug for post myocardial infarction in all type of patient at <http://www.trialresultscenter.org/go-Q277>
- secondary prevention for post myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q449>

## References

### PARIS, 1980:

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

### PARIS-II, 1986:

Klimt CR, Knatterud GL, Stamler J, Meier P, Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7:251-69 [2868029]

### PARIS, 1980:

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

## 2 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
<b>dipyridamol + aspirin vs placebo</b>			
<b>PARIS , 1980</b> n=810/406 follow-up: 41 months (mean)	Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Placebo	patients who had recovered from myocardial infarction	Parallel groups Double blind USA and UK
<b>PARIS-II , 1986</b> n=1563/1565 follow-up: 23.4 months	Aspirin (330 mg) + dipyridamole (75 mg) 3x/d versus Placebo	patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously	Parallel groups Double blind USA and UK
<b>dipyridamol + aspirin vs aspirin</b>			
<b>PARIS , 1980</b> n=810/810 follow-up: 41 months	Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Aspirin (324 mg) 3x/d	patients who had recovered from myocardial infarction	Parallel groups Double blind USA and GB

More details and results :

- antiplatelets drug for cardiovascular prevention in secondary prevention in patients with CAD at <http://www.trialresultscenter.org/go-Q276>

## References

### PARIS, 1980:

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

### PARIS-II, 1986:

Klimt CR, Knatterud GL, Stamler J, Meier P, Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7:251-69 [2868029]

### PARIS, 1980:

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

## 3 thrombosis prevention

Trial	Treatments	Patients	Trials design and methods
<b>dipyridamol + aspirin vs control</b>			
Parodi I , 1973 n=40/22	Dip,A1000+Dip versus control	-	open
Parodi II , 1973 n=91/35	A1500,Dip,A+Dip versus control	-	open
Australian I , 1975 n=75/75	A1000+Dip versus control	-	open
Australian II , 1976 n=85/75	A1000+Dip versus control	-	open
Toulouse I , 1979 n=38/66	A990+Dip versus control	-	open
Zekert-III , 1977 n=135/46	A1500,A1300+Dip,A1000+Dip versus control	-	open
Harjola DVT , 1982 n=300/100	A1500,Dip,A+Dip versus control	-	open
Weiss , 1977 n=30/36	A990+Dip versus control	-	open
<b>dipyridamol + aspirin vs placebo</b>			
Encke IA , 1976 n=21/9	A990,A+Dip versus Placebo	-	double-blind
Encke IB , 1976 n=62/34	A1500,A990+Dip versus Placebo	-	double-blind

More details and results :

- antithrombotics for thrombosis prevention in general surgery at <http://www.trialresultscenter.org/go-Q92>
- antiplatelets drug for thrombosis prevention in general surgery at <http://www.trialresultscenter.org/go-Q461>
- antiplatelets drug for thrombosis prevention in all type of patients at <http://www.trialresultscenter.org/go-Q462>

## References

### **Parodi I, 1973:**

Parodi JC, Grandi A, Font E, Rotondaro D, Iorio J, Manrique J. El dipiridamol y el acido acetilsalicilico en la profilaxis de las trombosis venosas postoperatorias de los miembros inferiores Dia Med 1973;45:92-3.

### **Parodi II, 1973:**

Parodi JC, Grandi A, Font E, Rotondaro D, Iorio J, Manrique J. El dipiridamol y el acido acetilsalicilico en la profilaxis de las trombosis venosas postoperatorias de los miembros inferiores Dia Med 1973;45:92-3.

### **Australian I, 1975:**

O'Sullivan EF, Renney JT. Antiplatelet drugs in the prevention of postoperative deep vein thrombosis In: Proceedings of III congress of Interiational Societyfor Thrombosis andHaemnostasis (Washington). 1972:438.

### **Australian II, 1976:**

Renney JT, O'Sullivan EF, Burke PF Prevention of postoperative deep vein thrombosis with dipyridamole and aspirin. Br Med J 1976;1:992-4 [773495]

### **Toulouse I, 1979:**

Plante J, Boneu B, Vaysse C, Barret A, Gouzi M, Bierme R Dipyridamole-aspirin versus low doses of heparin in the prophylaxis of deep venous thrombosis in abdominal surgery. Thromb Res 1979;14:399-403 [442014]

### **Zekert-III, 1977:**

Zekert F. Prophylaxe von phlebothrombosen und lungenembolien mit aggregationshemmemn In: Zekert F, ed. Thrombosen, Embolien und Aggregatonshemmerin derChirurgie. Stuttgart: Schattauer, 1975:75-88.

### **Harjola DVT, 1982:**

Harjola P, Meurala H, Frick AMH. Prevention of deep venous theornboss and thrombo-embolism by dipyridamole and acetylsalicylic acid atter re.oastruvuve artenal surgery JCardotzasc Surg 1980U21:451-4.

### **Weiss, 1977:**

Weiss V, Jekiel M, Ritschard J, Bouvier CA. Prevetiun de la maladie thrombo-embolique post-op6ratoire par les anti-agregeants en chirurgie gyn6cologique Medecine et Hygiene (Geneve) 1977;35:943-4.

### **Encke IA, 1976:**

Encke A, Stock C, Dumke HO [Double-blind study for the prevention of postoperative thrombosis] Chirurg 1976;47:670-3 [1001131]

Schreiber U, Hartung B [Prevention of postoperative thromboembolism with micristin in general surgical patients (author's transl)] Zentralbl Chir 1979;104:1214-20 [543338]

### **Encke IB, 1976:**

Encke A, Stock C, Dumke HO [Double-blind study for the prevention of postoperative thrombosis] Chirurg 1976;47:670-3 [1001131]

## 4 coronary artery disease

Trial	Treatments	Patients	Trials design and methods
<b>dipyridamol + aspirin vs placebo</b>			
<b>PARIS , 1980</b> n=810/406 follow-up: 41 months (mean)	Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Placebo	patients who had recovered from myocardial infarction	Parallel groups Double blind USA and UK
<b>PARIS-II , 1986</b> n=1563/1565 follow-up: 23.4 months	Aspirin (330 mg) + dipyridamole (75 mg) 3x/d versus Placebo	patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously	Parallel groups Double blind USA and UK
<b>dipyridamol + aspirin vs aspirin</b>			
<b>PARIS , 1980</b> n=810/810 follow-up: 41 months	Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Aspirin (324 mg) 3x/d	patients who had recovered from myocardial infarction	Parallel groups Double blind USA and GB

More details and results :

- death and events prevention for coronary artery disease in all type of patients at <http://www.trialresultscenter.org/go-Q450>

CT

## References

### PARIS, 1980:

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

### PARIS-II, 1986:

Klimt CR, Knatterud GL, Stamler J, Meier P, Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7:251-69 [2868029]

### PARIS, 1980:

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

Entry terms: dipyridamol, dipyridamole monoacetate, dipyridamol monoacetate,